AcquiSci Inc. is a private NJ Company based at the NJIT Enterprise Development Center in the Newark Innovation Zone. AcquiSci is developing its medical-device based technological platform for the treatment of ischemic stroke, and other inflammatory-based diseases.

Joseph Latino and Linda Sharkus, Ph.D., founded AcquiSci Inc. in December of 2007. AcquiSci acquired d-OSAB™ in late September 2008 from a publicly traded company, LipidViro Tech, where Joseph Latino was Head of Research and Linda Sharkus was a Director.

The Company has attained approval to commence Phase IIa clinical trials for stroke in India and its development path is projected through the EU via the CE mark process and then into the US. To date, although approximately $3.5 million has been expended on the project, AcquiSci is at a comparable development stage for a neurological stroke treatment that would typically have resulted in $300-400 million in research costs!

AcquiSci’s technology is based on evoking a naturally occurring anti-inflammatory process in the body by inducing white blood cells, through a transfusion-like process, to undergo, what is known as apoptosis (programmed cell death). This causes a reduction of inflammation and increases cerebral blood flow by increasing anti-inflammatory chemicals secreted by the body in response to the reintroduction of the patient's own altered white cells.

AcquiSci is developing its medical device-based technology with an anti-inflammatory therapeutic platform known as d-OSAB™ (doseable-Oxidative Stressed Autologous Blood). It will appreciably widen the present window of treatment for ischemic stroke by four (4) to six (6) times.

The platform has therapeutic applications in other inflammatory diseases such as Chronic Heart Failure (CHF), and interestingly enough, in the sterilization of biofluids to prevent prion infectious contamination for products emanating from animals. Specifically, the inactivation of infectious prions, the rogue protein attributed to Mad Cow and Creutzfeldt-Jakob diseases.

The Company’s core technology patent was issued by the USPTO in June 2010 and there are US and International (through the Patent Cooperative Treaty agreement) patents pending to further protect the Company’s proprietary position.